Lv4
540 积分 2024-11-15 加入
Enlonstobart (SG001) plus platinum-based chemotherapy ± bevacizumab for first-line treatment of PD-L1 positive recurrent/metastatic cervical cancer: Safety run-in results of phase III randomized, double-blind, placebo-controlled study
3天前
已完结
Zimberelimab plus lenvatinib in patients with advanced cervical cancer who progressed after prior immune checkpoint inhibitors: A multicenter, single-arm, phase II trial
3天前
已关闭
AK104 combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer: Safety run-in results from the phase III AK104-305 study
3天前
已关闭
Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
3天前
已完结
Evaluation of the overall survival rates in locally advanced cervix cancer patients treated with radiotherapy alone and chemoradiation: A Brazilian experience
8天前
已关闭
Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study
9天前
已完结
A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study
9天前
已完结
Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer
9天前
已完结
Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer
10天前
已关闭
Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer
10天前
已关闭
皖公网安备34019202002308
